

Comments on “Tako-Tsubo syndrome in patients with COVID-19: a single center retrospective case series”

Josef Finsterer,¹ Claudia Stöllberger²

¹Neurology and Neurophysiology Center, Vienna; ²nd Medical Department, Klinik Landstrasse, Vienna, Austria

Dear Editor,

We read with interest the article by Alonzo *et al.* about a retrospective study of four patients with Takotsubo syndrome (TTS), which was attributed to SARS-CoV-2 infection (SC2I) [1]. All four patients had acute COVID-19 disease, which was confirmed by a polymerase chain reaction positive for SARS-CoV-2 and lung com-

puted tomography [1]. All four developed the classic TTS type and met the InterTAK diagnostic criteria [1]. It was concluded that COVID-19 may be a trigger for TTS, but the underlying pathophysiology remains unclear and may be multifactorial in nature [1]. The work is compelling, but some points should be discussed.

We disagree that none of the four patients had known triggers of TTS [1]. Since two of the four included patients had Alzheimer's disease (patient 1 and patient 2), we wonder how the authors ruled that TTS was due to Alzheimer's disease and not due to SC2I. Alzheimer's disease has been repeatedly reported to trigger TTS [2]. It has been suggested that the underlying pathophysiology of TTS in these patients is anxiety [2]. In particular, a change of location, such as a hospital admission, can lead to massive stress in Alzheimer's patients.

Furthermore, patient 2 had a history of permanent atrial fibrillation [1]. Atrial fibrillation is known to occur more frequently in TTS patients without triggers than in patients with an identified TTS trigger [3]. Therefore, it cannot be excluded that in patient 2, Alzheimer's disease in combination with atrial fibrillation triggered TTS and not SC2I.

Patient 3 had a history of colon cancer [1]. Since oncological patients are at increased risk of developing TTS due to emotional stress as well as physical stress after complete cancer therapy, it cannot be ruled out that SC2I was not the trigger for TTS. In this context, we should know the latency period between the diagnosis and treatment of colorectal cancer and the development of TTS.

Regarding patient 4, who had a coronary fistula to the pulmonary artery, there are several case reports of patients with coronary fistula and TTS. Coronary fistulas can be congenital or acquired from trauma or invasive cardiovascular procedures. Half of the patients with coronary fistulas suffer from angina pectoris, while the other half are discovered incidentally on echocardiography or coronary angiography performed for another reason.

A limitation of the study is that patient 2 did not undergo coronary angiography to rule out coronary artery disease. At least according to the Mayo Clinic criteria, coronary artery stenosis must be ruled out as an alternative pathophysiology.

Overall, the interesting study has limitations that challenge the results and their interpretation. Addressing these limitations could further strengthen and reinforce the statement of the study. Contrary to the main message of the work, triggers other than the SC2I were present in all four presented patients and could be responsible for the occurrence of TTS.

Correspondence: Josef Finsterer, Neurology and Neurophysiology Center, 1180 Vienna, Austria.
Tel. +43-1-5861075.
Fax. +43-1-5861075.
E-mail: ffigs1@yahoo.de

Key words: SARS-CoV-2, Takotsubo, apical ballooning, stress, COVID-19.

Contributions: JF, research project conception, organization, and execution, writing of the first draft, review and critique of the manuscript; CS, literature search, discussion, critical comments, final approval.

Conflict of interest: the authors declare that they have no competing interests, and all authors confirm accuracy.

Ethics approval and consent to participate: the authors confirm that the approval of an institutional review board or patient consent was not required for this work. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Availability of data and materials: all data are available from the corresponding author.

Funding: none.

Received: 20 September 2023.

Accepted: 6 November 2023.

Early view: 7 December 2023.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

©Copyright: the Author(s), 2023

Licensee PAGEPress, Italy

Monaldi Archives for Chest Disease 2024; 94:2787

doi: 10.4081/monaldi.2023.2787

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Alonzo A, Di Fusco SA, Castello L, et al. Tako-Tsubo syndrome in patients with COVID-19: a single center retrospective case series. *Monaldi Arch Chest Dis* 2024;94:2675.

2. Segers K, Mihailescu T, Kazadi A, et al. Takotsubo cardiomyopathy as a consequence of acute anxiety in a patient with Alzheimer's disease associated with Lewy body disease. *Psychogeriatrics* 2020;20:528-9.
3. Polednikova K, Kozel M, Linkova H, et al. Triggers, characteristics, and hospital outcome of patients with Takotsubo syndrome: 10 years experience in a large university hospital centre. *Eur Heart J Suppl* 2023;25:E10-6.